International study helps support FDA approval of HIV drug for newborns

An planetary survey conducted done the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network, including researchers astatine the University of California San Diego, helped pass the U.S. Food and Drug Administration's (FDA) caller support of dolutegravir, a second-generation integrase inhibitor, for the attraction of quality immunodeficiency microorganism (HIV-1) successful newborns from birth. The study, published successful The Lancet HIV, identified a dosing regimen that achieves due cause levels successful full-term newborns, supporting the usage of dolutegravir to dainty HIV from the archetypal days of life.